Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 13 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| STANDARD BIOTOOLS INC. | 62,975,000 | reported | 17 Nov 2025 | tx 8+1,677,780 |
| BIOLIFE SOLUTIONS INC | 4,757,165 | reported | 21 May 2026 | tx 14+1,863,229−1,350,000 |
| GeneDx Holdings Corp. | 3,507,164 | reported | 01 Aug 2024 | tx 3+454,555 |
| Fulcrum Therapeutics, Inc. | 599,285 | reported | 22 Jul 2019 | tx 5+604,285−3,250,000 |
| Decibel Therapeutics, Inc. | 546,421 | reported | 17 Feb 2021 | tx 3+1,121,421−2,896,032 |
| Verve Therapeutics, Inc. | 0 | reported | 21 Jun 2021 | tx 5+2,417,596−12,200,289 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 19 May 2026 | SALE | BIOLIFE SOLUTIONS INC | 300,000 | 22.65 USD | |
| 20 May 2026 | SALE | BIOLIFE SOLUTIONS INC | 250,000 | 23.70 USD | |
| 21 May 2026 | SALE | BIOLIFE SOLUTIONS INC | 650,000 | 23.70 USD | |
| 17 Nov 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 225,000 | 1.22 USD | |
| 13 Nov 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 450,000 | 1.20 USD | |
| 14 Nov 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 250,000 | 1.24 USD | |
| 09 Sept 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 100,000 | 1.29 USD | |
| 25 Aug 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 200,000 | 1.24 USD | |
| 22 Aug 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 200,000 | 1.26 USD | first after silence |
| 26 Aug 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 125,000 | 1.26 USD | |
| 01 Aug 2024 | OTHER | GeneDx Holdings Corp. | 413,655 | 32.25 USD | |
| 30 Apr 2024 | OTHER | BIOLIFE SOLUTIONS INC | 150,000 | 17.54 USD | |
| 30 Apr 2024 | OTHER | BIOLIFE SOLUTIONS INC | 150,000 | 17.54 USD | |
| 05 Mar 2024 | PURCHASE | GeneDx Holdings Corp. | 900 | 8.83 USD | |
| 04 Mar 2024 | PURCHASE | GeneDx Holdings Corp. | 40,000 | 8.74 USD | |
| 16 May 2023 | PURCHASE | BIOLIFE SOLUTIONS INC | 15,000 | 20.19 USD | first after silence |
| 18 May 2023 | PURCHASE | BIOLIFE SOLUTIONS INC | 30,000 | 21.76 USD | |
| 17 May 2023 | PURCHASE | BIOLIFE SOLUTIONS INC | 30,027 | 21.30 USD | |
| 04 Apr 2022 | GRANT_AWARD | STANDARD BIOTOOLS INC. | 127,780 | — | deriv |
| 21 Jun 2021 | CONVERSION | Verve Therapeutics, Inc. | 1,007,311 | — | |
| 21 Jun 2021 | CONVERSION | Verve Therapeutics, Inc. | 310,285 | — | |
| 21 Jun 2021 | PURCHASE | Verve Therapeutics, Inc. | 1,100,000 | 19.00 USD | anomaly |
| 21 Jun 2021 | CONVERSION | Verve Therapeutics, Inc. | 9,327,198 | — | deriv |
| 21 Jun 2021 | CONVERSION | Verve Therapeutics, Inc. | 2,873,091 | — | deriv |
| 17 Feb 2021 | PURCHASE | Decibel Therapeutics, Inc. | 575,000 | 18.00 USD |
2 purchases reported after at least 12 months of silence — most recent on 22 Aug 2025.